Please login to the form below

Not currently logged in
Email:
Password:

rovalpituzumab tesirine

This page shows the latest rovalpituzumab tesirine news and features for those working in and with pharma, biotech and healthcare.

Strike three for Rova-T has AbbVie cutting its losses

Strike three for Rova-T has AbbVie cutting its losses

Rova-T (rovalpituzumab tesirine) consists of an anti-DLL3 antibody linked to a cancer-killing agent called pyrrolo-benzodiazepine.

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...